Regulatory News:

Air Liquide (Paris:AI) is expanding its home healthcare business in Europe with the acquisition of Baywater Healthcare Ireland Limited, a major player in this activity in Ireland.

On the Irish market for 30 years, Baywater Healthcare Ireland Limited specializes in treating and monitoring respiratory diseases in the patient's home (oxygen therapy, continuous positive airway pressure and non-invasive ventilation). Baywater Healthcare Ireland Limited has 50 employees and cares for 10,000 patients, generating revenue of more than €12 million in 2014.

This acquisition marks a new geographical development for Air Liquide's home healthcare business, with the extension of its services to Ireland. Air Liquide will continue growing the company with the support of the existing team.

Pascal Vinet, Vice-President, Healthcare Global Operations and member of Air Liquide group’s Executive Committee commented: "The acquisition of this company, which is recognized for its expertise in the treatment of respiratory diseases and for its culture of innovation, is part of Air Liquide's growth strategy for the home healthcare business. It will allow us to develop on a new growth market in Europe."

Air Liquide Healthcare

supplies medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients.

In 2014, it served over 7,500 hospitals and 1,2 million patients at home throughout the world.

The Group’s Healthcare business reached € 2,570 million in revenues in 2014, with the support of its 12,000 employees.

 

The Home Healthcare Business

Air Liquide, European leader in home healthcare, provides home healthcare services in compliance with medical prescription for patients suffering from chronic diseases such as COPD (Chronic Obstructive Pulmonary Disease), sleep apnea and diabetes. These home healthcare services are being developed in addition to hospital care, enabling patients to enjoy better quality of life and local authorities to reduce costs. Home healthcare represents 50% of Air Liquide's revenue in Healthcare in 2014.

World leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with more than 50,000 employees and serves more than 2 million customers and patients. Oxygen, nitrogen and hydrogen have been at the core of the company’s activities since its creation in 1902. Air Liquide’s ambition is to be the leader in its industry, delivering long-term performance and acting responsibly.

Air Liquide ideas create value over the long term. At the core of the company’s development are the commitment and constant inventiveness of its people.

Air Liquide anticipates the challenges of its markets, invests locally and globally, and delivers high-quality solutions to its customers and patients, and the scientific community.

The company relies on competitiveness in its operations, targeted investments in growing markets and innovation to deliver profitable growth over the long-term.

Air Liquide’s revenues amounted to € 15.4 billion in 2014, and its solutions that protect life and the environment represented more than 40% of sales. Air Liquide is listed on the Paris Euronext stock exchange (compartment A) and is a member of the CAC 40 and Dow Jones Euro Stoxx 50 indexes.

www.airliquide.comFollow us on Twitter @AirLiquideGroup

Air LiquideCorporate CommunicationsCaroline Philips, +33 (0)1 40 62 50 84Anne Michaud, +33 (0)1 40 62 50 59orInvestor RelationsAude Rodriguez, +33 (0)1 40 62 57 08Louis Laffont, +33 (0)1 40 62 57 18orAir Liquide Healthcare CommunicationsMuriel Doucet, +33(0)1 49 69 46 46

C3 AI (NYSE:AI)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more C3 AI Charts.
C3 AI (NYSE:AI)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more C3 AI Charts.